Calsyntenin-2 promotes the pathology of acute myeloid leukemia via activation of the JAK2-STAT3 signaling pathway
- 25 October 2026
- journal article
- Published by Elsevier in Cellular Signalling
- Vol. 149, 112960
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 26 references indexed in Scilit:
- Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemiaCell Death & Disease, 2024
- A novel function of STAT3β in suppressing interferon response improves outcome in acute myeloid leukemiaCell Death & Disease, 2024
- ESRP1-driven alternative splicing of CLSTN1 inhibits the metastasis of gastric cancerCell Death Discovery, 2023
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic NeoplasmsLeukemia, 2022
- Mutant p53: it’s not all one and the sameCell Death & Differentiation, 2022
- A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In VivoCancer Cell, 2019
- Calsyntenins Function as Synaptogenic Adhesion Molecules in Concert with NeurexinsCell Reports, 2014
- The Calsyntenins—A Family of Postsynaptic Membrane Proteins with Distinct Neuronal Expression PatternsMolecular and Cellular Neuroscience, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Calsyntenin-1, a Proteolytically Processed Postsynaptic Membrane Protein with a Cytoplasmic Calcium-Binding DomainMolecular and Cellular Neuroscience, 2001